Jonathan Appleby, PhD CSO GSK Rare Diseases Cell and Gene Therapy

Jonathan joined GSK Rare Diseases in September 2010 as Medicines Development Leader for Strimvelis which became the first approved Ex Vivo CD34+ stem cell gene therapy.

He is also Chief Scientific Officer for the group supporting several projects and advising on new areas of research.

Prior to joining the Rare Diseases team Jonathan was part of the GSK Centre of Excellence for External Drug Discovery (CEEDD) where for 4 years he discovered, constructed and managed drug discovery alliances with US, European and Emerging Market companies covering a diverse range of discovery platforms in indications such as oncology, neurology, respiratory and anti-infectives.

He is a PhD qualified molecular biologist with two decades of pharmaceutical industry experience ranging from candidate selection through to approval and phase IV.